IRX5 and prostate adenocarcinoma: Compared with normal samples, KRT6A and MELTF showed significantly high expression in most cancer types, including LUAD (Figure S6C), while CRTAC1 was expressed lowly in most cancer types, including LUAD (Figure S6D, IRX5 was significantly highly expressed in breast cancer, CHOL, colon adenocarcinoma, kidney renal papillary cell carcinoma, liver hepatocellular carcinoma and READ tumours, while in KICH, kidney renal clear cell carcinoma, lung squamous cell carcinoma and PRAD, IRX5 was significantly lowly expressed (Figure S6E).